Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Masaki Ri

Showing results (21-30 of 116) with videos related to

Pageof 12
Sort By:
Gan to Kagaku Ryoho. Cancer & Chemotherapy|July 23, 2015
[Transplant-Related Mortality Following Allogeneic Hematopoietic Stem Cell Transplantation Using Fludarabine/Busulfan-Based Reduced-Intensity Conditioning - A Retrospective Analysis in a Single Institution]Takashi Yoshida, Shigeru Kusumoto, Arisa Masuda, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|December 20, 2016
Novel monitoring of hepatitis B reactivation based on ultra-high sensitive hepatitis B surface antigen assayNoboru Shinkai, Shigeru Kusumoto, Shuko Murakami, et al.
International Journal of Hematology|October 31, 2019
Final results of a phase I study of carfilzomib, lenalidomide, and dexamethasone for heavily pretreated multiple myelomaIsamu Sugiura, Kenshi Suzuki, Masaki Ri, et al.
Cancer Science|December 11, 2008
Bortezomib-induced apoptosis in mature T-cell lymphoma cells partially depends on upregulation of Noxa and functional repression of Mcl-1Masaki Ri, Shinsuke Iida, Takashi Ishida, et al.
Chemmedchem|January 10, 2014
Design, synthesis, and biological activity of NCC149 derivatives as histone deacetylase 8-selective inhibitorsTakayoshi Suzuki, Nobusuke Muto, Masashige Bando, et al.
Cancer Medicine|January 12, 2024
Low-dose fluconazole as a useful and safe prophylactic option in patients receiving allogeneic hematopoietic stem cell transplantationKentaro Hirade, Shigeru Kusumoto, Hiroya Hashimoto, et al.
Cancer Science|January 24, 2015
TM-233, a novel analog of 1'-acetoxychavicol acetate, induces cell death in myeloma cells by inhibiting both JAK/STAT and proteasome activitiesMorihiko Sagawa, Takayuki Tabayashi, Yuta Kimura, et al.
Asian Pacific Journal of Cancer Prevention : APJCP|July 28, 2023
The Relationship between Changes in Serum Element Concentrations and Pathological Condition and Disease Status in Japanese Multiple Myeloma Patients: A Pilot Study and Literature ReviewYuko Yamamoto, Masahiro Kondo, Yuji Hotta, et al.
International Journal of Hematology|October 10, 2020
Once-weekly vs. twice-weekly carfilzomib dosing in a subgroup of Japanese relapsed and refractory multiple myeloma patients from a randomized phase 3 trial (A.R.R.O.W.) and comparison with ENDEAVORNaoki Takezako, Hirohiko Shibayama, Hiroshi Handa, et al.
Plos One|June 27, 2015
Lipopolysaccharide-Induced CXCL10 mRNA Level and Six Stimulant-mRNA Combinations in Whole Blood: Novel Biomarkers for Bortezomib Responses Obtained from a Prospective Multicenter Trial for Patients with Multiple MyelomaTakashi Watanabe, Masato Mitsuhashi, Morihiko Sagawa, et al.
Pageof 12

Showing results (21-30 of 116) with videos related to

Sort By:
Pageof 12
Gan to Kagaku Ryoho. Cancer & Chemotherapy|July 23, 2015
[Transplant-Related Mortality Following Allogeneic Hematopoietic Stem Cell Transplantation Using Fludarabine/Busulfan-Based Reduced-Intensity Conditioning - A Retrospective Analysis in a Single Institution]Takashi Yoshida, Shigeru Kusumoto, Arisa Masuda, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|December 20, 2016
Novel monitoring of hepatitis B reactivation based on ultra-high sensitive hepatitis B surface antigen assayNoboru Shinkai, Shigeru Kusumoto, Shuko Murakami, et al.
International Journal of Hematology|October 31, 2019
Final results of a phase I study of carfilzomib, lenalidomide, and dexamethasone for heavily pretreated multiple myelomaIsamu Sugiura, Kenshi Suzuki, Masaki Ri, et al.
Cancer Science|December 11, 2008
Bortezomib-induced apoptosis in mature T-cell lymphoma cells partially depends on upregulation of Noxa and functional repression of Mcl-1Masaki Ri, Shinsuke Iida, Takashi Ishida, et al.
Chemmedchem|January 10, 2014
Design, synthesis, and biological activity of NCC149 derivatives as histone deacetylase 8-selective inhibitorsTakayoshi Suzuki, Nobusuke Muto, Masashige Bando, et al.
Cancer Medicine|January 12, 2024
Low-dose fluconazole as a useful and safe prophylactic option in patients receiving allogeneic hematopoietic stem cell transplantationKentaro Hirade, Shigeru Kusumoto, Hiroya Hashimoto, et al.
Cancer Science|January 24, 2015
TM-233, a novel analog of 1'-acetoxychavicol acetate, induces cell death in myeloma cells by inhibiting both JAK/STAT and proteasome activitiesMorihiko Sagawa, Takayuki Tabayashi, Yuta Kimura, et al.
Asian Pacific Journal of Cancer Prevention : APJCP|July 28, 2023
The Relationship between Changes in Serum Element Concentrations and Pathological Condition and Disease Status in Japanese Multiple Myeloma Patients: A Pilot Study and Literature ReviewYuko Yamamoto, Masahiro Kondo, Yuji Hotta, et al.
International Journal of Hematology|October 10, 2020
Once-weekly vs. twice-weekly carfilzomib dosing in a subgroup of Japanese relapsed and refractory multiple myeloma patients from a randomized phase 3 trial (A.R.R.O.W.) and comparison with ENDEAVORNaoki Takezako, Hirohiko Shibayama, Hiroshi Handa, et al.
Plos One|June 27, 2015
Lipopolysaccharide-Induced CXCL10 mRNA Level and Six Stimulant-mRNA Combinations in Whole Blood: Novel Biomarkers for Bortezomib Responses Obtained from a Prospective Multicenter Trial for Patients with Multiple MyelomaTakashi Watanabe, Masato Mitsuhashi, Morihiko Sagawa, et al.
Pageof 12